Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer's disease
View abstract on PubMed
Summary
This summary is machine-generated.Spatial extent of amyloid beta (Aβ) better detects early Alzheimer's disease (AD) changes than Aβ level. This measure also improves prediction of cognitive decline and tau spread in preclinical AD.
Area Of Science
- Neuroimaging
- Alzheimer's Disease Research
- Biomarker Discovery
Background
- Amyloid beta (Aβ) deposition is a hallmark of Alzheimer's disease (AD).
- Traditional Aβ positron emission tomography (PET) measures Aβ level (LVL).
- Early detection of Aβ in preclinical AD is crucial for intervention.
Purpose Of The Study
- To evaluate if spatial extent (EXT) of Aβ is more sensitive than Aβ LVL for detecting early Aβ deposits.
- To determine if Aβ EXT improves prediction of cognitive decline and tau proliferation.
- To enhance understanding of Aβ's role in preclinical AD.
Main Methods
- Used Pittsburgh Compound-B (PIB)-PET scans from 261 cognitively unimpaired older adults.
- Measured Aβ LVL (neocortical PIB DVR) and Aβ spatial extent (EXT) as the proportion of neocortex with elevated PIB.
- Longitudinally tracked Aβ deposits and cognitive changes.
Main Results
- Aβ EXT enabled earlier detection of Aβ deposits compared to traditional Aβ LVL.
- EXT improved the prediction of cognitive decline (Preclinical Alzheimer Cognitive Composite) and tau proliferation (flortaucipir-PET).
- Early Aβ deposits were spatially heterogeneous, with cognition and tau more closely tied to EXT than LVL.
Conclusions
- Spatial extent (EXT) of Aβ may be a more sensitive measure than Aβ level for detecting early changes in preclinical Alzheimer's disease.
- Aβ EXT improves the understanding of Aβ's association with tau proliferation and cognitive decline.
- Aβ EXT may enhance the targeting of individuals for Alzheimer's disease prevention trials.

